Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients. - Trial NCT05681819
Access comprehensive clinical trial information for NCT05681819 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 41 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Hengrui Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 1
Feb 20, 2023
Aug 18, 2025
Primary Outcome
To assess the number of patients with adverse events (AEs),To assess the number of patients with clinically significant change from baseline in vital signs values,,To assess the number of patients with clinically significant change in physical examination,,To assess the number of patients with clinically significant change from baseline in laboratory examination,,To assess the number of patients with clinically significant change from baseline in 12-ECG values,,To assess the number of patients with clinically significant change in brain MRI (cerebral edema, microbleeding, etc.)
Summary
Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of
 SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild
 Alzheimer's Disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05681819
Non-Device Trial